Biohaven Ltd.
215 Church Street
New Haven, CT 06510
United States
203 404 0410
https://www.biohaven.com
版塊: Healthcare
行業: Biotechnology
全職員工: 239
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Vladimir Coric M.D. | Chairman & CEO | 1.96M | 無 | 1971 |
| Mr. Matthew Buten | Chief Financial Officer | 1.05M | 無 | 1961 |
| Dr. Bruce D. Car DACVP, Ph.D. | Chief Scientific Officer | 883.03k | 無 | 1962 |
| Ms. Kimberly Gentile | Senior Vice President of Clinical Operations | 858.65k | 無 | 1966 |
| Ms. Deb Young | Director of Regulatory Affairs & Operations | 無 | 無 | 無 |
| Mr. George C. Clark | VP & Chief Accounting Officer | 無 | 無 | 1984 |
| Ms. Jennifer Porcelli | Vice President of Investor Relations | 無 | 無 | 無 |
| Mr. Warren Volles J.D. | General Counsel & Chief Legal Officer | 無 | 無 | 無 |
| Mr. Clifford Bechtold M.S. | President, GM of Biohaven Ireland & Chief Compliance Officer | 無 | 無 | 無 |
| Mr. John Tilton | Chief Commercial Officer of Rare Diseases | 無 | 無 | 1968 |
描述
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
公司管治
截至 2024年5月1日 止，Biohaven Ltd. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：2；董事會：8；股東權利：3；現金賠償：8。
